Case-control studies on ceruloplasmin and superoxide dismutase (SOD1) in neurodegenerative diseases: a short review.
This short review describes a series of case-control studies on the concentration and oxidative activity of ceruloplasmin (CP) in serum and the activity of superoxide dismutase (SOD1) in erythrocytes in patients with Alzheimer's disease (AD), Parkinson's disease (PD) and Down's syndrome (DS). The same parameters were re-examined in the PD patients 5 years later. The specific oxidative activity (oxidative activity related to mass) of CP was calculated in PD and DS. In AD and PD the oxidative activity of CP and SOD1 activity was significantly lower in patients than controls. The specific oxidative activity of CP was also significantly lower in PD patients. The difference in all parameters determined was still present 5 years later in PD patients. There was no difference in the concentration or activity of CP in patients with DS and controls. Because of the gene-dose effect (the gene for SOD1 is located on chromosome 21); the SOD1 activity was 50% higher in the patients than the controls. The CP specific oxidative activity and SOD1 activity were found to be significantly lower in the older (>40 years) than the younger DS patients. Whether changes in CP and SOD1 in AD, PD and DS are primary changes or a result of prolonged disease burden needs to be examined.
Torsdottir
Gudlaug
G
Department of Pharmacology and Toxicology, University of Iceland, Iceland. gudlaugt@hi.is
Kristinsson
Jakob
J
Snaedal
Jón
J
Sveinbjörnsdóttir
Sigurlaug
S
Gudmundsson
Grétar
G
Hreidarsson
Stefán
S
Jóhannesson
Torkell
T
D016022:Case-Control Studies; D002570:Ceruloplasmin / Q000378:metabolism*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000097:blood*; D013482:Superoxide Dismutase / Q000097:blood*; D000072105:Superoxide Dismutase-1
C000606290:SOD1 protein, human; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D002570:Ceruloplasmin